Magnesium Sulfate Injection Rx
Generic Name and Formulations:
Magnesium sulfate 500mg/mL; soln for IM inj; or IV use after dilution; contains aluminum.
Various generic manufacturers
Indications for Magnesium Sulfate Injection:
Mild deficiency: 1g IM every 6 hours for four doses. Severe deficiency: 250mg/kg IM within a period of 4 hours if necessary; alternatively 5g may be added to one liter of 5% dextrose inj or 0.9% sodium chloride inj for slow IV infusion over a 3-hour period. TPN: usual range: 1–3g (8–24mEq) daily. Severe renal impairment: max 20g in 48 hours.
TPN for infants: usual range: 0.25–1.25g (2–10mEq) daily.
Heart block. Myocardial damage.
Renal impairment. Monitor serum magnesium levels; if repeated doses are given, test knee jerk reflexes before each dose. Have injectable calcium salt readily available to counteract magnesium intoxication. Elderly. Premature neonates. Pregnancy (Cat.D). Nursing mothers.
Additive CNS depressant effects with barbiturates, narcotics, other hypnotics; adjust dose. Potentiates neuromuscular blocking agents. Concomitant cardiac glycosides; use extreme caution, heart block may occur.
Magnesium intoxication (eg, flushing, sweating, hypotension, depressed reflexes, flaccid paralysis, hypothermia, circulatory collapse, cardiac and CNS depression proceeding to respiratory paralysis.
Formerly known under the brand name Sulfamag.
Clinical Pain Advisor Articles
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Tools to Address the Opioid Crisis
- Methamphetamine Use on the Rise in Patients With Opioid Use Disorder
- Patterns of Non-Medical Prescription Opioid Use in Adolescents
- Half of the Responders to Our Poll Agree With the Approval of Dsuvia: We Want to Hear From You
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Cannabinoid-Associated Analgesia May Be Mediated Through Modulation of Affective Processes
- FDA Panel Votes in Favor of Abuse-Deterrent Oxycodone Reformulation
- FDA Proposes New Restrictions on Sale of Electronic Nicotine Delivery Systems
- Central Sensitization in Greater Trochanteric Pain Syndrome
- Pain Acceptance May Reduce Headache-Related Disability in Migraine
- FDA Issues Safety Alert Regarding Intrathecal Delivery of Pain Meds